

Mohammad Hojjat-Farsangi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2676899/publications.pdf>

Version: 2024-02-01

118
papers

3,624
citations

147566

31
h-index

161609

54
g-index

122
all docs

122
docs citations

122
times ranked

5419
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of Emerging Plant-Derived Nanoparticles as a Novel Approach for Nano-Drug Delivery Systems. <i>Immunological Investigations</i> , 2022, 51, 1039-1059.	1.0	27
2	TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4 ⁺ T cells in Preeclampsia Patients. <i>Immunological Investigations</i> , 2022, 51, 1023-1038.	1.0	15
3	Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. <i>Life Sciences</i> , 2022, 288, 120166.	2.0	10
4	Early stage evaluation of colon cancer using tungsten disulfide quantum dots and bacteriophage nano-biocomposite as an efficient electrochemical platform. <i>Cancer Nanotechnology</i> , 2022, 13, .	1.9	10
5	An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 92-97.	1.4	12
6	Oncostatin M: A mysterious cytokine in cancers. <i>International Immunopharmacology</i> , 2021, 90, 107158.	1.7	35
7	P47.10 Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2021, 16, S496.	0.5	0
8	Tâ€cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. <i>IUBMB Life</i> , 2021, 73, 726-738.	1.5	23
9	A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinibâ€resistant ROR1 ⁺ CLL cells. <i>EJHaem</i> , 2021, 2, 498-502.	0.4	3
10	Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy. <i>Cytokine</i> , 2021, 141, 155452.	1.4	38
11	Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection. <i>Viral Immunology</i> , 2021, 34, 531-541.	0.6	5
12	Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung. <i>Cell Death and Disease</i> , 2021, 12, 577.	2.7	11
13	Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. <i>Life Sciences</i> , 2021, 275, 119369.	2.0	22
14	Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo. <i>International Journal of Biological Macromolecules</i> , 2021, 186, 849-863.	3.6	23
15	Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules. <i>Handbook of Experimental Pharmacology</i> , 2021, 269, 75-99.	0.9	5
16	Identification of genes and miRNAs associated with angiogenesis, metastasis, and apoptosis in colorectal cancer. <i>Gene Reports</i> , 2020, 18, 100552.	0.4	7
17	Blockage of immune checkpoint molecules increases Tâ€cell priming potential of dendritic cell vaccine. <i>Immunology</i> , 2020, 159, 75-87.	2.0	67
18	Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression. <i>Life Sciences</i> , 2020, 260, 118423.	2.0	22

#	ARTICLE	IF	CITATIONS
19	IL-10-producing B cells play important role in the pathogenesis of recurrent pregnancy loss. <i>International Immunopharmacology</i> , 2020, 87, 106806.	1.7	27
20	Immunoreactivity pattern of monoclonal antibodies against Hepatitis B vaccine with global Hepatitis B virus genotypes. <i>Clinica Chimica Acta</i> , 2020, 510, 203-210.	0.5	4
21	Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression. <i>International Journal of Biological Macromolecules</i> , 2020, 149, 487-500.	3.6	56
22	Berberine: A novel therapeutic strategy for cancer. <i>IUBMB Life</i> , 2020, 72, 2065-2079.	1.5	44
23	Intrauterine administration of autologous hCG- activated peripheral blood mononuclear cells improves pregnancy outcomes in patients with recurrent implantation failure; A double-blind, randomized control trial study. <i>Journal of Reproductive Immunology</i> , 2020, 142, 103182.	0.8	28
24	EP4 receptor as a novel promising therapeutic target in colon cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153247.	1.0	17
25	Exosome: From leukemia progression to a novel therapeutic approach in leukemia treatment. <i>BioFactors</i> , 2020, 46, 698-715.	2.6	9
26	Concomitant blockade of A2AR and CTLA4 by siRNA loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T cell responses. <i>Journal of Cellular Physiology</i> , 2020, 235, 10068-10080.	2.0	30
27	Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102240.	1.7	23
28	ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. <i>Biomedicines</i> , 2020, 8, 170.	1.4	19
29	PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. <i>Life Sciences</i> , 2020, 247, 117437.	2.0	33
30	Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152915.	1.0	39
31	Nanomedicine for improvement of dendritic cell-based cancer immunotherapy. <i>International Immunopharmacology</i> , 2020, 83, 106446.	1.7	30
32	Tumor associated macrophages in the molecular pathogenesis of ovarian cancer. <i>International Immunopharmacology</i> , 2020, 84, 106471.	1.7	18
33	The Association between Inflammatory Cytokines and miRNAs with Slow Coronary Flow Phenomenon. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2020, 19, 56-64.	0.3	10
34	CDK1 in Breast Cancer: Implications for Theranostic Potential. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 758-767.	0.9	57
35	Toxicity of Saffron Extracts on Cancer and Normal Cells: A Review Article. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 1867-1875.	0.5	25
36	Oxidative stress, inflammatory settings, and microRNA regulation in the recurrent implantation failure patients with metabolic syndrome. <i>American Journal of Reproductive Immunology</i> , 2019, 82, e13170.	1.2	37

#	ARTICLE	IF	CITATIONS
37	E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions. <i>Clinica Chimica Acta</i> , 2019, 498, 126-134.	0.5	33
38	S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 467-487.	1.6	37
39	Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. <i>Prostaglandins and Other Lipid Mediators</i> , 2019, 144, 106338.	1.0	79
40	Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior. <i>American Journal of Surgical Pathology</i> , 2019, 43, 409-421.	2.1	24
41	Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway. <i>International Journal of Biological Macromolecules</i> , 2019, 133, 436-445.	3.6	58
42	Altered T _H cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities. <i>Journal of Cellular Physiology</i> , 2019, 234, 4924-4933.	2.0	45
43	Promising immunotherapy: Highlighting cytokine-induced killer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8863-8883.	1.2	11
44	CD73 as a potential opportunity for cancer immunotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 127-142.	1.5	102
45	The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 5478-5487.	2.0	41
46	Metabolic syndrome mediates proinflammatory responses of inflammatory cells in preeclampsia. <i>American Journal of Reproductive Immunology</i> , 2019, 81, e13086.	1.2	27
47	Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis. <i>Journal of Cellular Physiology</i> , 2019, 234, 9943-9955.	2.0	29
48	Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9300-9314.	1.2	23
49	The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia. <i>Journal of Cellular Physiology</i> , 2019, 234, 5106-5116.	2.0	91
50	ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells. <i>Blood</i> , 2019, 134, 5312-5312.	0.6	3
51	Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells. <i>Blood</i> , 2019, 134, 2565-2565.	0.6	0
52	First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2018, 32, 2291-2295.	3.3	30
53	Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 2032-2057.	2.0	116
54	The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1415-1424.	2.5	201

#	ARTICLE	IF	CITATIONS
55	Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population. <i>Immunology Letters</i> , 2018, 204, 16-22.	1.1	22
56	Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. <i>Journal of Cellular Physiology</i> , 2018, 233, 7165-7177.	2.0	56
57	A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. <i>PLoS ONE</i> , 2018, 13, e0198038.	1.1	27
58	Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells. <i>PLoS ONE</i> , 2018, 13, e0192839.	1.1	3
59	Kisspeptin serum levels in acute myocardial infarction patients and healthy individuals. <i>Biomedical Research and Therapy</i> , 2018, 5, 2111-2118.	0.3	3
60	Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg). <i>Antiviral Research</i> , 2017, 144, 153-163.	1.9	10
61	Nanoparticles and targeted drug delivery in cancer therapy. <i>Immunology Letters</i> , 2017, 190, 64-83.	1.1	374
62	Recent advances in targeting mTOR signaling pathway using small molecule inhibitors. <i>Journal of Drug Targeting</i> , 2017, 25, 189-201.	2.1	21
63	Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia. <i>Tumor Biology</i> , 2016, 37, 11947-11957.	0.8	24
64	Mechanisms of tumor cell resistance to the current targeted-therapy agents. <i>Tumor Biology</i> , 2016, 37, 10021-10039.	0.8	60
65	Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis. <i>Journal of Immunotoxicology</i> , 2016, 13, 603-619.	0.9	38
66	First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor. <i>Annals of Oncology</i> , 2016, 27, vi530.	0.6	1
67	Ibrutinib-A double-edge sword in cancer and autoimmune disorders. <i>Journal of Drug Targeting</i> , 2016, 24, 373-385.	2.1	21
68	Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances. <i>Journal of Drug Targeting</i> , 2016, 24, 192-211.	2.1	14
69	Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy. <i>Current Drug Targets</i> , 2016, 17, 1687-1703.	1.0	11
70	Somatic Mutation in Immunoglobulin Gene Variable Region in Patients With Chronic Lymphoid Leukemia and Its Influence on Disease Prognosis. <i>Middle East Journal of Rehabilitation and Health Studies</i> , 2016, 3, .	0.1	0
71	Sero-Epidemiological Study of Hepatitis E Virus among Thalassemia as High Risk Patients: A Cross-Sectional Survey in Jahrom, Southern, Iran. <i>Global Journal of Health Science</i> , 2015, 8, 245.	0.1	8
72	Association of Tumor Growth Factor- β^2 and Interferon- β^3 Serum Levels With Insulin Resistance in Normal Pregnancy. <i>Global Journal of Health Science</i> , 2015, 8, 25.	0.1	4

#	ARTICLE	IF	CITATIONS
73	Lack of Association Between rs17568 Polymorphism in OX40 Gene and Myocardial Infarction, Southern of Iran. <i>Global Journal of Health Science</i> , 2015, 8, 41.	0.1	6
74	The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. <i>British Journal of Haematology</i> , 2015, 169, 455-458.	1.2	32
75	Novel and emerging targeted-based cancer therapy agents and methods. <i>Tumor Biology</i> , 2015, 36, 543-556.	0.8	28
76	Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. <i>Tumor Biology</i> , 2015, 36, 5727-5742.	0.8	96
77	The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2015, 11, 1567-1582.	1.1	25
78	First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells. <i>Blood</i> , 2015, 126, 2912-2912.	0.6	2
79	A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL. <i>Journal of Clinical Oncology</i> , 2015, 33, 8556-8556.	0.8	1
80	Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0142310.	1.1	12
81	Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies. <i>International Journal of Molecular Sciences</i> , 2014, 15, 13768-13801.	1.8	174
82	Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia. <i>Human Immunology</i> , 2014, 75, 170-175.	1.2	4
83	Ligation of human Fc receptor like-2 by monoclonal antibodies down-regulates B-cell receptor-mediated signalling. <i>Immunology</i> , 2014, 143, 341-353.	2.0	12
84	The receptor tyrosine kinase ROR1 – An oncofetal antigen for targeted cancer therapy. <i>Seminars in Cancer Biology</i> , 2014, 29, 21-31.	4.3	85
85	Abstract 4770: Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway. <i>Cancer Research</i> , 2014, 74, 4770-4770.	0.4	5
86	A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1. <i>Journal of Clinical Oncology</i> , 2014, 32, e13561-e13561.	0.8	4
87	Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. <i>Leukemia and Lymphoma</i> , 2013, 54, 843-850.	0.6	67
88	Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2013, 41, 615-626.	0.2	16
89	Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia. <i>Cytokine</i> , 2013, 62, 439-445.	1.4	20
90	T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 51-63.	2.0	16

#	ARTICLE	IF	CITATIONS
91	Increased Frequency of CD8 ⁺ and CD4 ⁺ Regulatory T Cells in Chronic Lymphocytic Leukemia: Association with Disease Progression. <i>Cancer Investigation</i> , 2013, 31, 121-131.	0.6	49
92	Construction and characterization of a new chimeric antibody against HER2. <i>Immunotherapy</i> , 2013, 5, 703-715.	1.0	10
93	Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells. <i>PLoS ONE</i> , 2013, 8, e61167.	1.1	50
94	The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells. <i>PLoS ONE</i> , 2013, 8, e78339.	1.1	54
95	Apoptosis induction mediated through PI3-kinase/AKT/mTOR pathway using anti-ROR1 monoclonal antibody in chronic lymphocytic leukemia cells.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7087-7087.	0.8	2
96	Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22198-e22198.	0.8	0
97	Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis. <i>Journal of Experimental Medicine</i> , 2012, 209, 291-305.	4.2	44
98	Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. <i>Leukemia</i> , 2012, 26, 1348-1355.	3.3	86
99	162 Investigation of TLR7/8 and 9 Agonists and CD40-ligand Costimulation on EBV Transformation of B Cells of Chronic Lymphocytic Leukemia. <i>European Journal of Cancer</i> , 2012, 48, S39.	1.3	0
100	Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein. <i>Journal of Clinical Immunology</i> , 2012, 32, 855-865.	2.0	30
101	Monoclonal Antibody Against ROR1 in Chronic Lymphocytic Leukemia Cells Induced Apoptosis Via PI3-Kinase/AKT/CREB Pathway. <i>Blood</i> , 2012, 120, 1769-1769.	0.6	1
102	Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6557-6557.	0.8	3
103	Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 4583-4583.	0.6	6
104	Phosphorylation of Receptor Tyrosine Kinase ROR1 At Tyrosine 641, 646 and Serine 652 residues Might Be of Importance for the Survival of CLL Leukemic Cells. <i>Blood</i> , 2012, 120, 3885-3885.	0.6	0
105	9209 POSTER Unbalanced Frequency of Regulatory T Cells in Different Subsets of Chronic Lymphocytic Leukemia. <i>European Journal of Cancer</i> , 2011, 47, S642.	1.3	0
106	1.7 Telomere Length and Expression of Human Telomerase Reverse Transcriptase Splice Variants in Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S145.	0.2	0
107	ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) - a Survival Factor for CLL Cells. <i>Blood</i> , 2011, 118, 1778-1778.	0.6	2
108	Patients with Chronic Lymphocyte Leukemia (CLL) Have Naturally Occurring Antibodies Against the Receptor Tyrosine Kinase (ROR1). <i>Blood</i> , 2011, 118, 1771-1771.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias. <i>Avicenna Journal of Medical Biotechnology</i> , 2011, 3, 119-25.	0.2	8
110	Expression Profile of Galectin-1 and Galectin-3 Molecules in Different Subtypes of Chronic Lymphocytic Leukemia. <i>Cancer Investigation</i> , 2010, 28, 717-725.	0.6	22
111	Ror1 Targeting Monoclonal Antibodies Induced Apoptosis of Chronic Lymphocytic Leukemia Cellsâ€“ A Potential Novel Therapeutic Approach. <i>Blood</i> , 2010, 116, 916-916.	0.6	1
112	Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 2061-2070.	0.6	34
113	Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. <i>Cancer Science</i> , 2009, 100, 2346-2353.	1.7	29
114	Fc receptorâ€“like 1â€“5 molecules are similarly expressed in progressive and indolent clinical subtypes of Bâ€“cell chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2008, 123, 2113-2119.	2.3	30
115	Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia. <i>Human Immunology</i> , 2008, 69, 666-674.	1.2	13
116	Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 109-116.	0.6	20
117	Assessment of the immune system in 55 Iranian patients with vitiligo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 706-711.	1.3	28
118	Construction and characterization of a new chimeric antibody against HER2. <i>Frontiers in Immunology</i> , 0, 4, .	2.2	0